Bempedoic Acid TBM BE study in SBOA [BE/BA News]

posted by dshah  – India/United Kingdom, 2022-03-30 19:09 (244 d 15:04 ago) – Posting: # 22889
Views: 744

(edited by dshah on 2022-03-31 11:42)

Hello All!

I was going through SBOA of Bempedoic acid marketed as Nexleton tablets.
In general, a BE study of Phase III vs TBM formulation can suffice the need for clinical significance. But in what condition, FDA can waive such condition of BE of TBM formulation with Phase III formulations in IND filing? [image]
or considering the biopharmaceutics risk assessment- it is a low risk and study can be waived?
[image]
Regards,
Divyen Shah

Complete thread:

UA Flag
Activity
 Admin contact
22,418 posts in 4,693 threads, 1,598 registered users;
17 visitors (0 registered, 17 guests [including 4 identified bots]).
Forum time: 09:13 CET (Europe/Vienna)

Intellect distinguishes between the possible and the impossible;
reason distinguishes between the sensible and the senseless.
Even the possible can be senseless.    Max Born

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5